MALDI imaging

Bruker Presents High-Value Life Science, Materials Research and Applied Market Solutions at Analytica 2022

Retrieved on: 
Tuesday, June 21, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Olive, MALDI, ISO, Chromatography, X-ray, GxP, Lipid, Protein, Metabolomics, Corporation, 3D, Plasma, Spatial, Software, AT, Life, ATR, Solution, Technology, EDS, Compliance, CEO, NIR, Xenobiotic, TGA, Nasdaq, Food, Doctor of Philosophy, Temperature, TG, Drug development, Hertz, MPA, Olive oil, Neuroscience, Biology, Chemistry, SLM, HYPERION, Ownership, Mass spectrometry, Analysis, MALDI imaging, Multimedia, HT, PON, Quality control, Proteomics, Cancer, Research, Microscopy, Optogenetics, Acquisition, 4D, Partnership, CFR, QCL, Cell biology, IonSense, Fine chemical, Ceramic, Microscope, Camera, Medical imaging, Bruker, Analytica

Bruker Corporation (Nasdaq: BRKR) this week displays its high-value scientific instrumentation, software and integrated solutions for applications in materials and energy research, biopharmaceuticals, applied markets, as well as life science and translational research at Analytica 2022 .

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) this week displays its high-value scientific instrumentation, software and integrated solutions for applications in materials and energy research, biopharmaceuticals, applied markets, as well as life science and translational research at Analytica 2022 .
  • Bruker is committed to providing optimized technological, software, chemistry and biology solutions to enable the success of our customers.
  • Bruker launches the HYPERION II FT-IR / IR Laser Imaging Microscope as a flexible research platform, combining FT-IR microscopy with QCL IR laser imaging.
  • Brukers high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.

Bruker Announces Key Innovations for Highly Multiplexed Spatial Proteomics and Multiomic Tissue Imaging at Large Field-of-View

Retrieved on: 
Monday, June 6, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Life, Experiment, Cell, Research, MALDI, Conference, TME, MALDI imaging, Medical University of South Carolina, Mass spectrometry, Marie Cassidy, Partnership, Disease, Nasdaq, Solution, Multimedia, Artifact, Â, Medical school, Bruker, Therapy, Microscopy, IHC, Tumor microenvironment, CCS, Technology, Lipid, Microgrid, Glycosylation, Cell biology, Pharmacology, Flex, Xenobiotic, Proteomics, Protein, Medical imaging, Fine chemical, Microscope

At the 70th ASMS Conference, Bruker Corporation (Nasdaq: BRKR) announced key innovations for spatial multiomics of tissue and tumor microenvironments (TME).

Key Points: 
  • At the 70th ASMS Conference, Bruker Corporation (Nasdaq: BRKR) announced key innovations for spatial multiomics of tissue and tumor microenvironments (TME).
  • Following Brukers strategic partnership with AmberGen1, key enhancements are introduced for MALDI HiPLEX-IHC mass spectrometry imaging.
  • Using AmberGens MiralysTM antibody-based photocleavable peptide mass tags, highly multiplexed IHC staining and photocleavage of peptide markers fit seamlessly into Brukers IntelliSlide-based automated workflows for MALDI imaging.
  • Novel multiomic imaging enhances spatial high-plex protein imaging with the ability to elucidate metabolic processes in the same tissue section.

Bruker Announces Major Advances in CCS-Enabled 4D Proteomics at ASMS

Retrieved on: 
Tuesday, November 2, 2021
Other Health, Software, Research, Radiology, Medical Devices, Technology, Genetics, Science, Biotechnology, Other Technology, Other Science, Health, Online, Peptide, Dana–Farber Cancer Institute, MALDI, DDA, Life, ASMS, Multimedia, Biochemistry, Paser, Acquisition, MCP, Bruker, RNA transfection, Biology, Research, University, Machine learning, RNA, PRM, EDT, Scripps, Nature Methods, Cell biology, Solution, IRT, SCP, CCS, Microscopy, Compass, DRS, Protein, LLC, Laboratory, Nasdaq, Proteome, MALDI imaging, Method, Berlin, BioRxiv, Proteomics, FDR, Nucleotide, Dana, Ambiguity, Algorithm, Utrecht University, Time, Conference, Phosphorylation, Maxis, Automation, 3D printing, Fine chemical, Medical imaging

At the 69th ASMS meeting in Philadelphia, Bruker Corporation (Nasdaq: BRKR) announced novel CCS-enabled 4D proteomics for major capability enhancements for timsTOF Pro 2, timsTOF fleX and timsTOF SCP mass spectrometers.

Key Points: 
  • At the 69th ASMS meeting in Philadelphia, Bruker Corporation (Nasdaq: BRKR) announced novel CCS-enabled 4D proteomics for major capability enhancements for timsTOF Pro 2, timsTOF fleX and timsTOF SCP mass spectrometers.
  • Vadim Demichev and Markus Ralser at the Charit Universittsmedizin Berlin, Bruker is now integrating CCS-enabled DIA-NN into PaSER GPU-powered proteomics software for the timsTOF platform for enhanced identification and quantification.
  • Were also pleased to see Bruker incorporating the open-source version of Vadim Demichevs DIA-NN in its PaSER real-time proteomics workflows and look forward to working with Bruker to further improve 4D-Proteomics workflows.
  • Dr. Marto will present at the Bruker Press Conference at ASMS on November 2nd at 11 am EDT.

Waters Sets New Standard in High Resolution Mass Spectrometry with SELECT SERIES Multi Reflecting Time-of-Flight Platform

Retrieved on: 
Tuesday, June 8, 2021
Oncology, Medical devices, Health, Research, Science, Biotechnology, Laboratory techniques, Mass spectrometry, Chemistry, Physical sciences, Ion source, Chemical pathology, Clinical pathology, Matrix-assisted laser desorption/ionization, MALDI imaging, Mass Rapid Transit, Waters Corporation, Spectrometer

Waters Corporation (NYSE:WAT) today introduced the Waters SELECT SERIES MRT, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced DESI and new MALDI imaging sources.

Key Points: 
  • Waters Corporation (NYSE:WAT) today introduced the Waters SELECT SERIES MRT, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced DESI and new MALDI imaging sources.
  • The SELECT SERIES MRT platform is the basis for the next generation of Waters high-resolution mass spectrometers.
  • The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market todayii.
  • Customer shipments of the SELECT SERIES MRT are expected to begin in the fourth quarter of this year.

Frontier Diagnostics Initiates Operations Using Imaging Mass Spectrometry for Cancer Detection

Retrieved on: 
Tuesday, December 15, 2020
Instrumental analysis, Mass spectrometry, Ion source, Biochemistry methods, Mass spectrometry imaging, Matrix-assisted laser desorption/ionization, Matrix, MALDI imaging, Iknife

NASHVILLE, Tenn., Dec. 15, 2020 /PRNewswire/ -- Frontier Diagnostics, a cancer diagnostics company, today announced that it has begun developing and validating a clinical assay for melanoma diagnosis, by direct tissue analysis, using matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry.

Key Points: 
  • NASHVILLE, Tenn., Dec. 15, 2020 /PRNewswire/ -- Frontier Diagnostics, a cancer diagnostics company, today announced that it has begun developing and validating a clinical assay for melanoma diagnosis, by direct tissue analysis, using matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry.
  • Frontier Diagnostics also announced that it has purchased assets from New River Labs, LLC, a company that made significant investments in imaging mass spectrometry diagnostics in recent years.
  • Norris and Caprioli, internationally known for pioneering imaging mass spectrometry, are faculty members at Vanderbilt University and direct the National Resource for Imaging Mass Spectrometry.
  • Frontier Diagnostics holds several patents for the use of imaging mass spectrometry in diagnostics.

Bruker Launches timsTOF fleX™ with ESI and MALDI for SpatialOMx™

Retrieved on: 
Friday, May 31, 2019
Mass spectrometry, Omics, Biochemistry methods, Ion source, Chemistry, Proteomics, MALDI imaging, Physical sciences, Matrix-assisted laser desorption/ionization, Natural sciences

The timsTOF fleX comes with Bruker's proprietary 10kHz SmartBeam 3D laser with true pixel fidelity for rapid, label-free MALDI imaging at high-spatial resolution, while fully preserving the unparalleled 4D proteomics and phenomics sensitivity of the timsTOF Pro in ESI mode.

Key Points: 
  • The timsTOF fleX comes with Bruker's proprietary 10kHz SmartBeam 3D laser with true pixel fidelity for rapid, label-free MALDI imaging at high-spatial resolution, while fully preserving the unparalleled 4D proteomics and phenomics sensitivity of the timsTOF Pro in ESI mode.
  • MALDI-guided spatialOMx on the timsTOF fleX enables the profiling of spatially-defined tissue regions, thereby allowing subsequent 4D proteomics to selectively target cell-type sub-populations.
  • The robust, ultra-high sensitivity timsTOF fleX bridges the divide between molecular tissue imaging and body fluids analysis by offering nanoLC-TIMS-MS/MS on the same instrument.
  • Bruker is also launching IntelliSlides specifically designed to automate timsTOF fleX workflows.